This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease


Lee, Jae-Hong, Sevigny, Jeff


Alzheimer Disease And Associated Disorders, Volume: 25, No.: 1, Pages.: 58-62

Year of Publication



The rationale for the development of the rivastigmine transdermal patch was to improve upon an efficacious therapy by mitigating certain adverse events, such as nausea and vomiting. This may be particularly important in Alzheimer disease patients with low body weights, who may be more susceptible to these adverse events. This analysis compared the effect of body weight on tolerability in Alzheimer disease patients receiving rivastigmine capsules or rivastigmine patch. Using data from a 24-week trial, adverse events and discontinuations were evaluated in patients stratified on the basis of extreme low weight (<50 kg), medium weight (50 to 80 kg), and high weight (>80 kg) at baseline. Rivastigmine patch was generally well tolerated, regardless of patient body weight. Among patients receiving rivastigmine patch, lower body weight, as stratified, was not associated with a higher adverse event rate; however, there was an association between a higher adverse event rate and low body weight among patients receiving rivastigmine capsules. Discontinuations because of adverse events were not directly related to weight. A lower incidence of adverse events was apparent with transdermal delivery of rivastigmine compared with oral administration.; Copyright © 2011 by Lippincott Williams & Wilkins

Bibtex Citation

@article{Lee_2011, doi = {10.1097/wad.0b013e3181f32829}, url = {}, year = 2011, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {25}, number = {1}, pages = {58--62}, author = {Jae-Hong Lee and Jeff Sevigny}, title = {Effects of Body Weight on Tolerability of Rivastigmine Transdermal Patch}, journal = {Alzheimer Disease {&} Associated Disorders} }


administration & dosage, administration oral, adverse, adverse effects, aged, alzheimer disease, body weight, double-blind method, drug therapy, events, female, humans, male, medication, neuroprotective agents, phenylcarbamates, rivastigmine, therapeutic use, tolerability, transdermal patch

Types of Dementia

Alzheimer’s Disease

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime